Philippe Gabriel Steg.

We discovered no advantage of ivabradine in reducing the chance of cardiovascular events. Previous observational studies show that an elevated heartrate is connected with an increased threat of cardiovascular events in populations with steady coronary artery disease.2-4,15,16 The lack of good thing about ivabradine in SIGNIFY contrasts with outcomes from previous post hoc analyses with this agent suggesting that it would improve outcomes in sufferers with stable coronary artery disease.10,11 In addition, in patients with heart failure, the decrease in heartrate with ivabradine has been shown to improve clinical outcomes, beyond the improvements observed with beta-blockers.9,17 Although the study population in SIGNIFY had a high prevalence of risk factors owing to the inclusion criteria, the annual incidence of the primary end point was relatively low , probably due to the background therapy the sufferers were receiving, that was administered according to current suggestions.Appel, M.D., Gabriel Contreras, M.D., M.P.H., Laura Lisk, B.Sc., and Neil Solomons, M.D. For the ALMS Group: Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis Systemic lupus erythematosus is an autoimmune disorder often seen as a the development of glomerulonephritis. 1 Renal involvement remains the strongest predictor of mortality and morbidity among sufferers with lupus,1 and despite improvements in the administration of lupus, the incidence of end-stage renal disease hasn’t declined.2 Management of lupus nephritis includes induction therapy to attain remission and long-term maintenance therapy to avoid relapse, progression to end-stage renal disease, and death.3 However, your options for long-term therapy stay controversial.